Trials / Recruiting
RecruitingNCT01887340
Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma
Therapeutic Strategy Guided by PET-TDM for Patients With Grade I or Metastatic Seminoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 271 (estimated)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the ration of patients getting an lighten therapeutic strategy after 18F-fluoro-désoxyglucose positron emission tomography (PET-TDM) in grade I (cohort 1) or metastatic (cohort 2) seminoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carboplatin | \- carboplatine: Dose (mg) = AUC x (GFR + 25) * GFR : glomérulaire filtration (ml/min) * AUC : area under curve (mg/ml x min) |
| DRUG | Etoposide | 100 mg/m2 D1 to D5 |
| DRUG | Cisplatin | 20 mg/m2 de D1 to D5 |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2016-06-01
- Completion
- 2026-06-01
- First posted
- 2013-06-26
- Last updated
- 2016-06-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01887340. Inclusion in this directory is not an endorsement.